Allogene Therapeutics ALLO Lease Liability Payments - Remainder of Fiscal Year
Lease Liability Payments - Remainder of Fiscal Year at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's lease liability payments - remainder of fiscal year.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's lease liability payments - remainder of fiscal year?
- Allogene Therapeutics (ALLO) reported lease liability payments - remainder of fiscal year of $13.57M in Q1 2026.
- How has Allogene Therapeutics's lease liability payments - remainder of fiscal year changed year-over-year?
- Allogene Therapeutics's lease liability payments - remainder of fiscal year increased by 3.1% year-over-year, from $13.16M to $13.57M.
- What does lease liability payments - remainder of fiscal year mean?
- The contractual cash obligations for operating and finance leases due within the remaining months of the current fiscal year. This provides a short-term view of the company's fixed lease commitments. It is a critical component for assessing near-term liquidity and cash flow requirements.